cytidylyl-3--5--guanosine and Hepatitis-B--Chronic

cytidylyl-3--5--guanosine has been researched along with Hepatitis-B--Chronic* in 1 studies

Other Studies

1 other study(ies) available for cytidylyl-3--5--guanosine and Hepatitis-B--Chronic

ArticleYear
CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV.
    International journal of biological sciences, 2022, Volume: 18, Issue:1

    Chronic Hepatitis B virus (CHB) infection is a global public health problem. Oligodeoxynucleotides (ODNs) containing class C unmethylated cytosine-guanine dinucleotide (CpG-C) motifs may provide potential adjuvants for the immunotherapeutic strategy against CHB, since CpG-C ODNs stimulate both B cell and dendritic cell (DC) activation. However, the efficacy of CpG-C ODN as an anti-HBV vaccine adjuvant remains unclear. In this study, we demonstrated that CpG M362 (CpG-C ODN) as an adjuvant in anti-HBV vaccine (cHBV-vaccine) successfully and safely eliminated the virus in HBV-carrier mice. The cHBV-vaccine enhanced DC maturation both

    Topics: Adjuvants, Immunologic; Animals; Dinucleoside Phosphates; Disease Models, Animal; Hepatitis B Vaccines; Hepatitis B, Chronic; Male; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides

2022